Readers researching the broader hepatocyte growth factor / c-Met pathway for cognitive indications should be aware that Fosgonimeton (development code ATH-1017), a structurally distinct small-molecule prodrug developed by Athira Pharma as an HGF positive modulator, has been investigated in three clinical trials in dementia indications
Furthermore, the salts of the present invention are very favorable due to the absence of any signs of toxicity up to doses of 50 mg/kg b.w., (body weight)
The initial stages, N1 and N2, represent lighter sleep phases, whereas N3, equated with SWS, signifies the deepest phase of sleep
they are suited for different research goals
For laboratories studying this compound further, Elite Research Labs provides COA-verified GHK-Cu research peptide designed specifically for laboratory research